News Agency
The Times

Celltrion presents additional data from phase III randomized controlled trials to further support biosimilarity for CT-41 (biosimilar candidate of denosumab) and CT-P47 (biosimilar candidate of tocilizumab) at American College of Rheumatology (ACR) Conver

  • Written by PR Newswire
Celltrion presents additional data from phase III randomized controlled trials to further support biosimilarity for CT-41 (biosimilar candidate of denosumab) and CT-P47 (biosimilar candidate of tocilizumab) at American College of Rheumatology (ACR) Conver
  • 78-Week results from Phase III randomized controlled trial (RCT) including switching data from reference denosumab to CT-P41 (biosimilar candidate of denosumab) demonstrate comparable efficacy and safety results; Results support the therapeutic equivalence of CT-P41 and reference denosumab in treating postmenopausal women with osteoporosis (PMO)[1]...

Read more: Celltrion presents additional data from phase III randomized controlled trials to further support...

Google Ads Agency Sydney: How to Generate More Qualified Leads With Paid Search

When someone searches Google for a service they need immediately, appearing at the right moment can be extremely valuable. Unlike many traditional marketing channels, paid search can place a business in front of people who are already researching a product... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion